Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when Evusheld will be available on the NHS.

The Department has asked the National Institute for Health and Care Excellence (NICE) as the independent expert body to develop guidance for the National Health Service on the clinical and cost effectiveness of Evusheld in its licensed indications for the treatment and prevention of COVID-19. NICE will develop guidance in line with its established methods and processes for health technology evaluation which are published and available at the following link:

https://www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation.

NICE is appraising Evusheld for the treatment of COVID-19 alongside other licensed therapeutics and currently expects to publish final guidance in March 2023. NICE’s final guidance on Evusheld for the prevention of COVID-19 is currently expected in April 2023. The NHS in England is legally required to fund medicines recommended by NICE, usually within three months of final guidance.